The present invention discloses a genetically engineered Kluyveromyces sp. yeast cell comprising at least a genetic modification that inactivates or deletes a nucleic acid sequence encoding for transcription factor SEQ ID No. 2, particularly Haal. The genetically engineered yeast cell according to this invention has an improvement of lactic acid tolerance, lactic acid production or a combination thereof as compared to the parental.

A nutritional composition comprises fucosylated human milk oligosaccharide and/or sialylated human milk oligosaccha-ride, non-digestible, fermentable polysaccharide, and Bifidobacterium. The nutritional composition is free of short-chain fructooligosac-charide having at least about 50% of molecules with a degree of polymerization of less than about 5. A method of treating a subject at risk of developing a Clostridium difficile infection or a subject having a Clostridium difficile infection comprises administering such a nutritional composition.

A nutritional composition comprises fucosylated human milk oligosaccharide and/or sialylated human milk oligosaccha-ride, non-digestible, fermentable polysaccharide, and Bifidobacterium. The nutritional composition is free of short-chain fructooligosac-charide having at least about 50% of molecules with a degree of polymerization of less than about 5. A method of treating a subject at risk of developing a Clostridium difficile infection or a subject having a Clostridium difficile infection comprises administering such a nutritional composition.

Provided are a novel yeast strain producing glutathione and a method of producing glutathione using the same.

Provided are a novel yeast strain producing glutathione and a method of producing glutathione using the same.

This application relates to a pharmaceutical composition for anti-inflammation, including a probiotic and an antibiotic, and a method of preventing or treating inflammation by using the same. In one aspect, the method includes locally administrating a probiotic and an antibiotic to an inflamed area of a subject.

This application relates to a pharmaceutical composition for anti-inflammation, including a probiotic and an antibiotic, and a method of preventing or treating inflammation by using the same. In one aspect, the method includes locally administrating a probiotic and an antibiotic to an inflamed area of a subject.

Aspects of the disclosure relate to compositions and methods for dietary management of certain conditions, such as infectious diseases. The disclosure is based, in part, on methods of identifying one or more single nucleotide polymorphisms (SNPs) in a subject and preparing a personalized report recommending a mixture of nutritional supplements and/or dietary aids based upon the presence of the SNPs. In some embodiments, the disclosure provides personalized compositions comprising nutritional supplements for dietary management of immune health and COVID support.

Aspects of the disclosure relate to compositions and methods for dietary management of certain conditions, such as infectious diseases. The disclosure is based, in part, on methods of identifying one or more single nucleotide polymorphisms (SNPs) in a subject and preparing a personalized report recommending a mixture of nutritional supplements and/or dietary aids based upon the presence of the SNPs. In some embodiments, the disclosure provides personalized compositions comprising nutritional supplements for dietary management of immune health and COVID support.

Coronavirus Disease 2019 (COVID-19) remains a threat with the emergence of new variants, especially Delta and Omicron, without specific effective therapeutic drugs. The present invention provides a method and a composition for preventing and treating COVID-19 (SARS-CoV-2) coronavirus infection which includes administering to a subject in need thereof one or more therapeutically effective doses of Virofree which comprises a pharmaceutically acceptable combination of grape seed extract, acerola cherry extract, olive leaf extract, marigold extract, green tea extract, pomegranate extract, yeast beta-glucan and soya bean extract for a treatment period.